Skip to main content

Table 4 Summary the results of gastrectomy following systemic chemotherapy for stage IV gastric cancer

From: Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy

Reference

Author

Year

Metastasis

Regimen of chemotherapy

Patients who underwent gastrectomy

Whole study population (if it included non-surgery cases)

Prognostic factors

Number of patients

MST (months)

Number of patients

MST (months)

12

Nakajima et al.

1997

M1

FLEP (5-Fluorouracil, Leucovorin, Cisplatin, Etoposide)

19

NA

30

6.5

NA

13

Yano et al.

2002

unresectable (M0 + M1)

FEMTXP (5-Fluorouracil, Epirubicin, Methotrexate, Cisplatin) or THP-FLPM (Pirarubicin,5-Fluorouracil, Leucovorin, Cisplatin, Mitomycin C)

14

NA

33

NA

salvage surgery

14

Satoh et al.

2006

M0 + M1

S-1, Cisplatin

36

NA

45

21.8

NA

15

Ishigami et al.

2008

M1

Paclitaxel, S-1

18

25.7

R0 resection

16

Okabe et al.

2009

M1 (peritoneal metastasis)

S-1, Cisplatin

32

NA

41

20.4

NA

17

Suzuki et al.

2010

unresectable (M0 + M1)

Docetaxel, S-1

20

28.5

NA

18

Kanda et al.

2012

M1

S-1 based chemotherapy

28

29.0

histological tumor length (<  5 cm vs. ≥ 5 cm)

19

Satoh et al.

2012

M1

S-1, Cisplatin

44

NA

51

19.2

NA

20

Han et al.

2013

M1

Various

34

22.9 (R0 resection) and 7.8 (non-R0 resection)

ypN stage (N0–2 vs. N3)

21

Yabusaki et al.

2013

M1

S-1, Cisplatin

97

22.5

148

16.8

surgery, R0 resection, D2/D3 lymph node dissection, CR/PR response

22

Fukuchi et al.

2015

unresectable (M0 + M1)

S-1, Cisplatin or S-1, Paclitaxel

40

53.0

151

16.0

one non-curative factor, R0 resection

23

Kinoshita et al.

2015

M1

Docetaxel, Cisplatin, S-1

34

29.9

57

20.9

potential resectability

24

Ito et al.

2015

M1

Various

14

24.8

70

14.1

NA

Present study

  

M1

Various

101

26.0

curative resection (complete macroscopic resection), chemotherapy response (CR/PR) of metastatic site, change of CEA level

  1. MST median survival time, CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not available, CEA carcinoembryonic antigen